Eculizumab treatment for rescue of renal function in IgA nephropathy

Pediatr Nephrol. 2014 Nov;29(11):2225-8. doi: 10.1007/s00467-014-2863-y. Epub 2014 Jun 13.


Background: Immunoglobulin A (IgA) nephropathy is a chronic glomerulonephritis with excessive glomerular deposition of IgA1, C3 and C5b-9, which may lead to renal failure.

Case diagnosis/treatment: We describe the clinical course of an adolescent with rapidly progressive disease leading to renal failure in spite of immunosuppressive treatment. Due to refractory disease the patient was treated with eculizumab (anti-C5) for 3 months in an attempt to rescue renal function. Treatment led to clinical improvement with stabilization of the glomerular filtration rate and reduced proteinuria. Discontinuation of treatment led to a rapid deterioration of renal function. This was followed by a single dose of eculizumab, which again reduced creatinine levels temporarily.

Conclusions: Early initiation of eculizumab therapy in patients with progressive IgA nephropathy may have a beneficial effect by blocking complement-mediated renal inflammation.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Biopsy
  • Complement Inactivating Agents / therapeutic use*
  • Creatinine / blood
  • Glomerular Filtration Rate
  • Glomerulonephritis, IGA / drug therapy*
  • Glomerulonephritis, IGA / pathology*
  • Humans
  • Kidney / pathology*
  • Kidney Glomerulus / pathology
  • Male
  • Renal Insufficiency / etiology
  • Salvage Therapy / methods*


  • Antibodies, Monoclonal, Humanized
  • Complement Inactivating Agents
  • eculizumab
  • Creatinine